Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Bier spots: a benign vascular anomaly.

He A, Kwatra SG, Kim N, Braunstein I.

BMJ Case Rep. 2016 Feb 24;2016. pii: bcr2016214761. doi: 10.1136/bcr-2016-214761. No abstract available.

2.

Selective Binding of AIRAPL Tandem UIMs to Lys48-Linked Tri-Ubiquitin Chains.

Rahighi S, Braunstein I, Ternette N, Kessler B, Kawasaki M, Kato R, Matsui T, Weiss TM, Stanhill A, Wakatsuki S.

Structure. 2016 Mar 1;24(3):412-22. doi: 10.1016/j.str.2015.12.017. Epub 2016 Feb 11.

3.

Proteasomal degradation of preemptive quality control (pQC) substrates is mediated by an AIRAPL-p97 complex.

Braunstein I, Zach L, Allan S, Kalies KU, Stanhill A.

Mol Biol Cell. 2015 Nov 1;26(21):3719-27. doi: 10.1091/mbc.E15-02-0085. Epub 2015 Sep 2.

4.

VWA domain of S5a restricts the ability to bind ubiquitin and Ubl to the 26S proteasome.

Piterman R, Braunstein I, Isakov E, Ziv T, Navon A, Cohen S, Stanhill A.

Mol Biol Cell. 2014 Dec 15;25(25):3988-98. doi: 10.1091/mbc.E13-11-0697. Epub 2014 Oct 15.

5.

Mucinous nevus: report of a case and review of the literature.

Cobos G, Braunstein I, Abuabara K, Chu EY, James W.

JAMA Dermatol. 2014 Sep;150(9):1018-9. doi: 10.1001/jamadermatol.2013.9451. Review. No abstract available.

PMID:
25029469
6.
7.

Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.

Braunstein I, Gangadhar TC, Elenitsas R, Chu EY.

J Cutan Pathol. 2014 Jun;41(6):539-43. doi: 10.1111/cup.12318. Epub 2014 Mar 11.

PMID:
24517243
8.

Inherent asymmetry in the 26S proteasome is defined by the ubiquitin receptor RPN13.

Berko D, Herkon O, Braunstein I, Isakov E, David Y, Ziv T, Navon A, Stanhill A.

J Biol Chem. 2014 Feb 28;289(9):5609-18. doi: 10.1074/jbc.M113.509380. Epub 2014 Jan 15.

9.

Signal-peptide-mediated translocation is regulated by a p97-AIRAPL complex.

Glinka T, Alter J, Braunstein I, Tzach L, Wei Sheng C, Geifman S, Edelmann MJ, Kessler BM, Stanhill A.

Biochem J. 2014 Jan 15;457(2):253-61. doi: 10.1042/BJ20130710.

PMID:
24160817
10.

Antibiotic sensitivity and resistance patterns in pediatric staphylococcal scalded skin syndrome.

Braunstein I, Wanat KA, Abuabara K, McGowan KL, Yan AC, Treat JR.

Pediatr Dermatol. 2014 May-Jun;31(3):305-8. doi: 10.1111/pde.12195. Epub 2013 Aug 23.

11.

Treatment of dermatologic connective tissue disease and autoimmune blistering disorders in pregnancy.

Braunstein I, Werth V.

Dermatol Ther. 2013 Jul-Aug;26(4):354-63. doi: 10.1111/dth.12076. Review.

PMID:
23914893
12.

Eltrombopag-associated hyperpigmentation.

Braunstein I, Wanat KA, Elenitsas R, Xu X, Frey N, Rosenbach M.

JAMA Dermatol. 2013 Sep;149(9):1112-5. doi: 10.1001/jamadermatol.2013.5107. No abstract available.

PMID:
23884150
13.

Update on management of connective tissue panniculitides.

Braunstein I, Werth VP.

Dermatol Ther. 2012 Mar-Apr;25(2):173-82. doi: 10.1111/j.1529-8019.2012.01489.x.

14.
15.

Lenalidomide therapy in treatment-refractory cutaneous lupus erythematosus: histologic and circulating leukocyte profile and potential risk of a systemic lupus flare.

Braunstein I, Goodman NG, Rosenbach M, Okawa J, Shah A, Krathen M, Kovarik CL, Luning Prak E, Werth VP.

J Am Acad Dermatol. 2012 Apr;66(4):571-82. doi: 10.1016/j.jaad.2011.01.015. Epub 2011 Aug 6.

16.

Two different mitotic checkpoint inhibitors of the anaphase-promoting complex/cyclosome antagonize the action of the activator Cdc20.

Eytan E, Braunstein I, Ganoth D, Teichner A, Hittle JC, Yen TJ, Hershko A.

Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9181-5. doi: 10.1073/pnas.0804069105. Epub 2008 Jun 30.

17.

Childhood ALL and second neoplasms.

Maniar TN, Braunstein I, Keefe S, Hussen S, Abrams T, De Michele A, El-Deiry WS.

Cancer Biol Ther. 2007 Oct;6(10):1525-31. Epub 2007 Aug 23. Review.

PMID:
17952026
18.

Inhibitory factors associated with anaphase-promoting complex/cylosome in mitotic checkpoint.

Braunstein I, Miniowitz S, Moshe Y, Hershko A.

Proc Natl Acad Sci U S A. 2007 Mar 20;104(12):4870-5. Epub 2007 Mar 13.

20.

Roles of the anaphase-promoting complex/cyclosome and of its activator Cdc20 in functional substrate binding.

Eytan E, Moshe Y, Braunstein I, Hershko A.

Proc Natl Acad Sci U S A. 2006 Feb 14;103(7):2081-6. Epub 2006 Feb 2. Erratum in: Proc Natl Acad Sci U S A. 2006 Mar 28;103(13):5242.

21.

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.

Parry RV, Chemnitz JM, Frauwirth KA, Lanfranco AR, Braunstein I, Kobayashi SV, Linsley PS, Thompson CB, Riley JL.

Mol Cell Biol. 2005 Nov;25(21):9543-53.

22.

p53-dependent down-regulation of telomerase is mediated by p21waf1.

Shats I, Milyavsky M, Tang X, Stambolsky P, Erez N, Brosh R, Kogan I, Braunstein I, Tzukerman M, Ginsberg D, Rotter V.

J Biol Chem. 2004 Dec 3;279(49):50976-85. Epub 2004 Sep 15.

23.

Lactobacillus strains and vaginal ecology.

Cadieux P, Burton J, Gardiner G, Braunstein I, Bruce AW, Kang CY, Reid G.

JAMA. 2002 Apr 17;287(15):1940-1. No abstract available.

PMID:
11960535
24.

Human telomerase reverse transcriptase promoter regulation in normal and malignant human ovarian epithelial cells.

Braunstein I, Cohen-Barak O, Shachaf C, Ravel Y, Yalon-Hacohen M, Mills GB, Tzukerman M, Skorecki KL.

Cancer Res. 2001 Jul 15;61(14):5529-36.

25.

Co-occurrence of hepatocellular carcinoma and lymphoma in patients with hepatitis C virus cirrhosis.

Shapira MY, Muszkat M, Braunstein I, Gotsman I.

J Clin Gastroenterol. 2001 Apr;32(4):368-9.

PMID:
11276290
26.

Identification of a novel transcription factor binding element involved in the regulation by differentiation of the human telomerase (hTERT) promoter.

Tzukerman M, Shachaf C, Ravel Y, Braunstein I, Cohen-Barak O, Yalon-Hacohen M, Skorecki KL.

Mol Biol Cell. 2000 Dec;11(12):4381-91.

27.
28.

Citrobacter koseri isolated in Israel, 1972-83.

Altmann G, Sechter I, Braunstein I, Gerichter CB.

Isr J Med Sci. 1984 Nov;20(11):1056-60.

PMID:
6511332
29.

Scorpion sting: successful treatment with nonhomologous antivenin.

Pomeranz A, Amitai P, Braunstein I, Reichenberg Y, Finelt M, Drukker A.

Isr J Med Sci. 1984 May;20(5):451-2. No abstract available.

PMID:
6469568
30.

Extended scheme for serotyping Campylobacter jejuni: results obtained in Israel from 1980 to 1981.

Rogol M, Sechter I, Braunstein I, Gerichter CB.

J Clin Microbiol. 1983 Aug;18(2):283-6.

31.

Edwardsiella tarda isolated in Israel between 1961 and 1980.

Sechter I, Shmilovitz M, Altmann G, Seligmann R, Kretzer B, Braunstein I, Gerichter CB.

J Clin Microbiol. 1983 Apr;17(4):669-71.

32.

Antigenic scheme of Citrobacter koseri.

Sechter I, Altmann G, Cahan D, Braunstein I, Gerichter CB.

J Clin Microbiol. 1981 Dec;14(6):620-2.

33.

Clinical trial with an anti-rabies human diploid cell vaccine (HDCV).

Gerichter CB, Shtark J, Braunstein I.

Dev Biol Stand. 1978;41:241-4.

PMID:
381073
34.

Host-parasite relations in experimental trichinellosis in the course of various treatments.

Pambuccian G, Simionescu-Crăciun O, Cironeanu I, Braunstein I.

Wiad Parazytol. 1969;15(5):755-6. No abstract available.

PMID:
5367773
35.

The corticotherapy in experimental trichinellosis.

Pambuccian G, Cironeanu I, Braunstein I.

Wiad Parazytol. 1966;12(5):571-82. No abstract available.

PMID:
4289084

Supplemental Content

Loading ...
Support Center